Intravenous delivery of a uPAR-targeting CAR-M in cirrhosis models markedly reduced serum ALT and fibrosis-associated gene expression (Col1a1, Col2a1, Acta2), accompanied by increased hepatocyte proliferation and partial liver function recovery; adaptive immune responses were suggested by enhanced CD8 T cell–mediated killing post-phagocytosis, without severe adverse events (88). Here, ACTA2 is linked to Cirrhosis.